Innovance d dimer kit

Manufactured by Siemens

Sourced in United States

The Innovance D-dimer kit is a laboratory diagnostic product manufactured by Siemens. It is used to quantitatively measure D-dimer levels in human plasma or serum samples. D-dimer is a protein fragment that is released into the bloodstream when a blood clot is degraded. The Innovance D-dimer kit provides accurate and reliable results to support clinical decision-making.

Automatically generated - may contain errors

Lab products found in correlation

Fluoroskan ascent fl plate reader, by Thermo Fisher Scientific (1 mentions) Enzygnost f1 2, by Siemens (1 mentions) Bcs xp coagulation analyzer, by Siemens (1 mentions) Cobas instrument, by Roche (1 mentions) Cobas c702 instrument, by Roche (1 mentions) Elecsys immunoassay, by Roche (1 mentions) Pathromtin sl, by Siemens (1 mentions) Quant it picogreen dsdna assay, by Thermo Fisher Scientific (1 mentions)

4 protocols using innovance d dimer kit

Quantification of Hemostatic Markers

Check if the same lab product or an alternative is used in the 5 most similar protocols

F1.2 and TAT were measured using Enzygnost F1.2 (monoclonal) and Enzygnost TAT micro enzyme-linked immunosorbent assay kits (Siemens Healthcare Diagnostics, Marburg, Germany). The fibrin fragment D-dimer was measured using the Innovance D-dimer kit and a BCS XP coagulation analyzer (both Siemens Healthcare Diagnostics). All analyses were performed according to the manufacturer's instructions. Levels of thrombin and APC were measured using the thrombin– and APC–OECA as previously described.
10 (link)
11 (link)
Thrombin generation kinetics were measured using calibrated automated thrombography (CAT) (Thrombinoscope BV, Maastricht, the Netherlands) using standard reagents (Stago, Düsseldorf, Germany) and a Fluoroskan Ascent FL plate reader (Thermo Scientific) as described elsewhere.
13 (link)
Reference ranges for all parameters were previously established by analyzing plasma samples of healthy individuals. Normal plasma levels of thrombin and APC were found below the lower limit of quantification (LLOQ) of the assays.
10 (link)
11 (link)
Thus, the LLOQ was defined as the upper limit of the reference range of these parameters.

Friedrich M.J., Schmolders J., Rommelspacher Y., Strauss A., Rühl H., Mayer G., Oldenburg J., Wirtz D.C., Müller J, & Pötzsch B. (2018). Activity Pattern Analysis Indicates Increased but Balanced Systemic Coagulation Activity in Response to Surgical Trauma. TH Open: Companion Journal to Thrombosis and Haemostasis, 2(4), e350-e356.

+ Open protocol

+ Expand

Quantifying COVID-19 Immune Markers

Check if the same lab product or an alternative is used in the 5 most similar protocols

Levels of anti-SARS-CoV2-spike IgG antibodies were measured by an enzyme-linked immunosorbent assay (ELISA) using the Elecsys immunoassay (Roche Diagnostics, Mannheim, Germany) following the manufacturer’s specifications. A positive result was indicated by a value > 0.4 U/mL and the upper measurement limit was set to 2500 U/mL. C-reactive protein (CRP) was measured in serum by an article-enhanced immunological turbidity test, where the aggregates are determined turbidimetrically (Cobas instrument, Roche Diagnostics, Mannheim, Germany). Interleukin-6 (IL-6) was analyzed in plasma samples using the Immunological ECLIA test (ElektroChemiLuminescence ImmunoAssay) on the Cobas instrument (Roche Diagnostics, Mannheim, Germany). Activated Partial Thromboplastin Time (aPTT; reference value: 26–36 s) was measured photometrically (Pathromtin SL, Siemens Healthcare); D-dimers (reference value: <500 µg/L) were analyzed in citrate plasma by a particle-enhanced immunoturbidimetric assay (Innovance D-Dimer Kit, Siemens Healthcare). Anti-β2glycoprotein IgG antibodies and anticardiolipin antibodies were measured by a quantitative ELISA (Euroimmun, Lübeck, Germany). Glucose concentrations were determined in serum using the GLUC3 assay on a Cobas c702 instrument (Roche Diagnostics GmbH, Mannheim, Germany).

Meisinger C., Kirchberger I., Warm T.D., Hyhlik-Dürr A., Goßlau Y, & Linseisen J. (2022). Elevated Plasma D-Dimer Concentrations in Adults after an Outpatient-Treated COVID-19 Infection. Viruses, 14(11), 2441.

+ Open protocol

+ Expand

Biomarkers for Thrombotic Complications

Check if the same lab product or an alternative is used in the 5 most similar protocols

D-dimer was tested using immunoturbidimetry in citrated PPP with an Innovance D-dimer kit in a CS5100 analyzer (Siemens Healthineers), and plasma values above 500 ng/mL are considered pathological by our central laboratory. Anti-PF4 Abs were determined in the serum samples using the ELISA method (00615 Asserachrom HPIA [IgG/A/M], Stago). According to the manufacturer’s instructions, a sample was considered positive if its optic density (OD) was greater than 0.7, value corresponding to 23% of OD of the kit's positive control. The results between 23% and 46% were considered weak positive and ≥46% strong positive. The cell-free DNA (cfDNA) was determined in citrated PPP using the Quant-iT PicoGreen dsDNA assay (Thermo Fisher Scientific). Plasminogen activator inhibitor-1 (PAI-1) in serum was tested with an ELISA kit from Invitrogen (Thermo Fisher Scientific) and range of normality established by the kit manufacturers' instructions.

Butta N.V., Arias-Salgado E.G., Monzón Manzano E., Acuña P., Álvarez Román M.T., Buño-Soto A., Ramos Ramos J.C., Belda-Iniesta C., Frías J., Carcas A.J., de Soto L.M., de Miguel Buckley R., Lora D., García-Morales M.T., Borobia A.M., Arribas J.R, & Jiménez Yuste V. (2023). No changes in hemostasis after COVID-19–heterologous vaccination schedule: A subanalysis of the phase 2 CombiVacS study. Research and Practice in Thrombosis and Haemostasis, 7(1), 100049.

+ Open protocol

+ Expand

Coagulation and Fibrinolysis Markers in Plasma

Check if the same lab product or an alternative is used in the 5 most similar protocols

All analyzed parameters were determined using the same, unthawed aliquot from each subject and each assay was performed on aliquots thawed for the same time. Commercial kits were used to determine the activity of C1-INH in serum (Quidel, San Diego, USA), and in citrated plasma the coagulation markers (prothrombin fragments 1 + 2 and thrombin-antithrombin complex, Enzygnost), the proteins of the fibrinolytic system (plasminogen: Berichrom Plasminogen kit, and PAI-1: Berichrom), the activation marker of fibrinolysis (D-dimer, Innovance D-dimer kit), as well as the activity of factor XI (Siemens Healthcare Diagnostics) and factor XII (Siemens Healthcare Diagnostics), according to the manufacturer’s instructions. Prothrombin time and activated partial thromboplastin time (aPTT) were determined by standard laboratory methods in citrated plasma. The level of fibrinogen was determined using the Clauss method using citrated plasma, where high levels of thrombin are added to diluted plasma and the time it takes for that thrombin to convert fibrinogen to fibrin correlates to the concentration of fibrinogen [31 (link)].

Csuka D., Veszeli N., Imreh É., Zotter Z., Skopál J., Prohászka Z., Varga L, & Farkas H. (2015). Comprehensive study into the activation of the plasma enzyme systems during attacks of hereditary angioedema due to C1-inhibitor deficiency. Orphanet Journal of Rare Diseases, 10, 132.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!